Schönlein-Henoch Purpura: Drug Therapy

Therapeutic targets

  • Improvement of the symptomatology
  • Avoidance of complications

Therapy recommendations

  • Local therapy: antiphlogistic (anti-inflammatory)-antimicrobial.
  • Systemic therapy
    • Corticosteroid therapy for severe forms, progression (progression) and extracutaneous manifestation.
  • In proteinuria (increased excretion of protein in the urine):
    • If persistent (persistent) for more than 6 weeks:
      • Small proteinuria (protein excretion <3.0 g/d): ACE inhibitor or angiotensin 1-(AT-1) receptor antagonist
      • Large proteinuria (> 3.0 g/d), nephrotic syndrome, nephritic syndrome, or nephrotic-nephritic syndrome, and proliferative histology (class III-IV): high-dose steroids (prednisone, methylprednisolone)
    • Over a period of 12 weeks: 3 steroid pulses (prednisolone 300-500 mg/m2 on alternate days) followed by oral prednisone (30 mg/m2 for 4 weeks) in descending doses (from week 5: 30 mg/m2 every 2nd day, from week 9: 15 mg/m2 every 2nd day for 2 weeks).
  • In case of life/organ threatening course or therapy resistance: additionally cyclophosphamide or high-dose immunoglobulin therapy (i. v.).